SCHEMBL21175150

SCHEMBL21175150

Cc1cc(-n2nc3c(c2-n2cc[nH]c2=O)[C@H](C)N(C(=O)O)CC3)cc(C)c1Cl

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 18/20 0.35
▸ CRHR1 P34998 1/20 0.31
▸ P2RX7 Q99572 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28952251 0.91 GLP1R (0.38) GLP1R
SCHEMBL21175410 0.91 GLP1R (0.38) GLP1R
SCHEMBL21175263 0.87 GLP1R (0.38) GLP1R
SCHEMBL26762581 0.80 GLP1R (0.31) GLP1RCRHR1
SCHEMBL21175207 0.79 GLP1R (0.35) GLP1RCRHR1
SCHEMBL21175193 0.79 P2RX7 (0.34) P2RX7
SCHEMBL26122776 0.79 GLP1R (0.36) GLP1R
Hydrochloric Acid SCHEMBL21175370 0.79 — —
SCHEMBL20014818 0.77 GLP1R (0.31) GLP1R
SCHEMBL21183679 0.76 GLP1R (0.36) GLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4349840-A2 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-04-10 — — EP disclosed
EP-3517538-B1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI PHARMACEUTICAL CO LTD (JP) 2024-03-13 — — EP disclosed
US-20230382912-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-30 — — US disclosed
US-11814381-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-14 — — US disclosed
EP-4134367-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-02-15 — — EP disclosed
US-20210017176-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-01-21 — — US disclosed
US-10858356-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-12-08 — — US disclosed
EP-3517538-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT Chugai Seiyaku Kabushiki Kaisha (JP) 2019-07-31 — — EP disclosed
US-20190225604-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2019-07-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225604-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR GLP1R 1/4885CRHR1 350/4885P2RX7 292/4885
US-20230382912-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR GLP1R 1/4885CRHR1 350/4885P2RX7 292/4885
US-20210017176-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR GLP1R 1/4885CRHR1 358/4885P2RX7 121/4885
US-11814381-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR GLP1R 1/4885CRHR1 350/4885P2RX7 112/4885
US-10858356-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR GLP1R 1/4885CRHR1 350/4885P2RX7 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback